Analyzing Retrophin (RTRX) and Its Competitors
Retrophin (NASDAQ: RTRX) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Retrophin to similar companies based on the strength of its valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.
Institutional and Insider Ownership
50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 2.9% of Retrophin shares are owned by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of current recommendations and price targets for Retrophin and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Retrophin currently has a consensus price target of $36.00, indicating a potential upside of 67.36%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.83%. Given Retrophin’s stronger consensus rating and higher probable upside, research analysts plainly believe Retrophin is more favorable than its peers.
Volatility & Risk
Retrophin has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Retrophin’s peers have a beta of 8.49, meaning that their average share price is 749% more volatile than the S&P 500.
Earnings & Valuation
This table compares Retrophin and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Retrophin||$133.59 million||-$47.90 million||-14.25|
|Retrophin Competitors||$284.28 million||$34.29 million||76.13|
Retrophin’s peers have higher revenue and earnings than Retrophin. Retrophin is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Retrophin and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.